Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 517

Showing 1-25 of 517 citing articles:

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1579
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Joerg Herrmann, Daniel J. Lenihan, Saro H. Armenian, et al.
European Heart Journal (2021) Vol. 43, Iss. 4, pp. 280-299
Open Access | Times Cited: 397
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 211
The role of cellular senescence in cardiac disease: basic biology and clinical relevance
Mozhdeh Mehdizadeh, Martín Aguilar, Éric Thorin, et al.
Nature Reviews Cardiology (2021) Vol. 19, Iss. 4, pp. 250-264
Closed Access | Times Cited: 182
Vascular toxic effects of cancer therapies
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 503-522
Open Access | Times Cited: 151
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Javid J. Moslehi, Andrew H. Lichtman, Arlene H. Sharpe, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 5
Open Access | Times Cited: 146
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
Néstor Rubio‐Infante, Yoel A. Ramírez‐Flores, Elena C. Castillo, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 10, pp. 1739-1747
Open Access | Times Cited: 127
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies
Girish Chandra Arya, Kamalpreet Kaur, Vikas Jaitak
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113511-113511
Closed Access | Times Cited: 112
Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy
Wentao Xia, Zixuan Tao, Bin Zhu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9118-9118
Open Access | Times Cited: 112
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 527-542
Open Access | Times Cited: 112
Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin
Kai Hou, Jianliang Shen, Junrong Yan, et al.
EBioMedicine (2021) Vol. 69, pp. 103456-103456
Open Access | Times Cited: 111
Drug-induced oxidative stress in cancer treatments: Angel or devil?
Hao Jiang, Jing Zuo, Bowen Li, et al.
Redox Biology (2023) Vol. 63, pp. 102754-102754
Open Access | Times Cited: 97
Coronary blood flow in heart failure: cause, consequence and bystander
Gerd Heusch
Basic Research in Cardiology (2022) Vol. 117, Iss. 1
Open Access | Times Cited: 79
Cardiovascular disease and cancer: shared risk factors and mechanisms
Nicholas S. Wilcox, Uri Amit, Jacob B. Reibel, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 9, pp. 617-631
Closed Access | Times Cited: 73
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Yumin Wang, Jing Hu, Shuang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 72
WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis
Panpan Tai, Xinyu Chen, Guihua Jia, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010
Carolyn Larsen, Mariana Garcia‐Arango, Harika Dasari, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254669-e2254669
Open Access | Times Cited: 50
Cardiotoxic effects of common and emerging drugs: role of cannabinoid receptors
Yi-Ming Bo, Xin Zhao, Liliang Li
Clinical Science (2024) Vol. 138, Iss. 6, pp. 413-434
Closed Access | Times Cited: 24
Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study
Qingui Chen, Nienke van Rein, Tom van der Hulle, et al.
European Heart Journal (2024) Vol. 45, Iss. 25, pp. 2201-2213
Open Access | Times Cited: 16
Trends, Characteristics and Outcomes in Breast Cancer Survivors With STEMI
Jia Ee Chia, Song Peng Ang, Muhammed Haris Usman, et al.
Angiology (2025)
Closed Access | Times Cited: 2
Implication of Gut Microbiota in Cardiovascular Diseases
Wenyi Zhou, Yiyu Cheng, Ping Zhu, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-14
Open Access | Times Cited: 116
MRI-traceable theranostic nanoparticles for targeted cancer treatment
Tareq Anani, Shiva Rahmati, Sultana Nayer, et al.
Theranostics (2020) Vol. 11, Iss. 2, pp. 579-601
Open Access | Times Cited: 99
The cancer patient and cardiology
José Luis Zamorano, Christer Gottfridsson, Riccardo Asteggiano, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 12, pp. 2290-2309
Open Access | Times Cited: 92
Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association
Michael G. Fradley, Theresa M. Beckie, Sherry Brown, et al.
Circulation (2021) Vol. 144, Iss. 3
Open Access | Times Cited: 86
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Giorgio Frega, Qi Wu, Julie Le Naour, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 79
Page 1 - Next Page

Scroll to top